{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:28:03Z","timestamp":1756384083154,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:p>Actinic keratoses are common, often multiple, epidermal lesions found mainly on the sun-exposed skin of fair-skinned middle-aged and older people.<jats:sup>1<\/jats:sup> Over time, lesions may remain unchanged or may proliferate, regress, reappear or develop into squamous cell carcinoma (SCC).<jats:sup>2<\/jats:sup> Detectable (spot) lesions are often associated with alteration of the surrounding skin (field) where subclinical lesions might be present.<jats:sup>2<\/jats:sup> Interventions may target individual or multiple lesions or a whole field.<jats:sup>2<\/jats:sup> Here, we update our previous review<jats:sup>3<\/jats:sup> on the prevention and treatment of actinic keratoses, focusing on the licensed treatments most commonly used in the UK and recommended in UK guidelines.<\/jats:p>","DOI":"10.1136\/dtb.2013.7.0193","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T20:46:59Z","timestamp":1372970819000},"page":"81-84","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Management of actinic keratosis"],"prefix":"10.1136","volume":"51","member":"239","published-online":{"date-parts":[[2013,7,4]]},"reference":[{"key":"2025082701451859000_51.7.81.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07692.x"},{"key":"2025082701451859000_51.7.81.2","doi-asserted-by":"crossref","unstructured":"Gupta AK . Interventions for actinic keratoses. Cochrane Database Syst Rev 2012, Issue 12. Art. No.: CD004415. DOI: 10.1002\/14651858.CD004415.pub2.","DOI":"10.1002\/14651858.CD004415.pub2"},{"key":"2025082701451859000_51.7.81.3","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2002.40533"},{"key":"2025082701451859000_51.7.81.4","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth","year":"2006","journal-title":"Eur J Dermatol"},{"key":"2025082701451859000_51.7.81.5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1468-3083.2011.04356.x","article-title":"Photodynamic therapy for actinic keratosis in organ transplant patients","volume":"27","author":"Basset-Seguin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082701451859000_51.7.81.6","first-page":"335","article-title":"Actinic keratosis: how to differentiate the good from the bad ones?","volume":"16","author":"Quaedvlieg","year":"2006","journal-title":"Eur J Dermatol"},{"key":"2025082701451859000_51.7.81.7","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1524-4725.2012.02452.x","article-title":"Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach","volume":"38","author":"Ritchie","year":"2012","journal-title":"Dermatol Surg"},{"key":"2025082701451859000_51.7.81.8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00420-010-0532-4","article-title":"UV-induced skin cancer at workplace and evidence-based prevention","volume":"83","author":"K\u00fctting","year":"2010","journal-title":"Int Arch Occup Environ Health"},{"key":"2025082701451859000_51.7.81.9","first-page":"241","article-title":"What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents","volume":"89","author":"Berman","year":"2012","journal-title":"Cutis"},{"key":"2025082701451859000_51.7.81.10","unstructured":"Joint Formulary Committee. British National Formulary. Edition 65 (March\u2013September 2013). London: BMJ Group and Pharmaceutical Press, 2013."},{"key":"2025082701451859000_51.7.81.11","unstructured":"European Medicines Agency, 2012. Zyclara imiquimod. EPAR summary for the public [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002387\/human_med_001586.jsp&mid=WC0b01ac058001d124 [Accessed 20 June 2013]."},{"key":"2025082701451859000_51.7.81.12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CIA.S31930","article-title":"Optimal treatment of actinic keratoses","volume":"8","author":"Uhlenhake","year":"2013","journal-title":"Clin Intervent Aging"},{"key":"2025082701451859000_51.7.81.13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","article-title":"Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results","volume":"165","author":"Stockfleth","year":"2011","journal-title":"Br J Dermatol"},{"key":"2025082701451859000_51.7.81.14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1517\/14656566.2012.716039","article-title":"Pharmacotherapy of actinic keratosis: an update","volume":"13","author":"Berman","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2025082701451859000_51.7.81.15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4155\/cli.12.83","article-title":"Emerging medical treatments for actinic keratoses, squamous cell carcinoma and basal cell carcinoma","volume":"2","author":"Ghuznavi","year":"2012","journal-title":"Clin Investig"},{"key":"2025082701451859000_51.7.81.16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/09546630903341937","article-title":"Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment","volume":"21","author":"Kaur","year":"2010","journal-title":"J Dermatol Treat"},{"key":"2025082701451859000_51.7.81.17","first-page":"1432","article-title":"A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes","volume":"10","author":"Foley","year":"2011","journal-title":"J Drug Dermatol"},{"key":"2025082701451859000_51.7.81.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.006"},{"key":"2025082701451859000_51.7.81.19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1468-3083.2009.03430.x","article-title":"Guidelines for practical use of MAL-PDT in non-melanoma skin cancer","volume":"24","author":"Christensen","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082701451859000_51.7.81.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08882.x"},{"key":"2025082701451859000_51.7.81.21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2133.2010.10098.x","article-title":"A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate","volume":"164","author":"Serra-Guillen","year":"2011","journal-title":"Br J Dermatol"},{"key":"2025082701451859000_51.7.81.22","first-page":"1","article-title":"Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference","volume":"88","author":"Del Rosso","year":"2011","journal-title":"Cutis"},{"key":"2025082701451859000_51.7.81.23","unstructured":"All Wales Medicines Strategy Group, 2012. Fluorouracil\/salicylic acid (Actikerall\u00ae) [online]. Available: http:\/\/www.wales.nhs.uk\/sites3\/ docmetadata.cfm?orgid=371&id=192646 [Accessed 20 June 2013]."},{"key":"2025082701451859000_51.7.81.24","unstructured":"Scottish Medicines Consortium, 2011. Fluorouracil+salicylic acid (Actikerall) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/728_11_5_flououracil_salicylic_acid_Actikerall\/5_fluorouracil_Salicylic_acid_Actikerall [Accessed 19 June 2013]."},{"key":"2025082701451859000_51.7.81.25","unstructured":"National Institute for Heakth and Care Excellence, 2013. ESNM14: Actinic keratosis: ingenol mebutate gel. [online]. Available: http:\/\/publications.nice.org.uk\/esnm14-actinic-keratosis-ingenol-mebutate-gel-esnm14\/overview [Accessed 20 June 2013]."},{"key":"2025082701451859000_51.7.81.26","unstructured":"All Wales Therapeutics and Toxicology Centre, 2013. AWMSG Secretariat Assessment Report. Ingenol mebutate (Picato\u00ae) 150 micrograms\/g gel and 500 micrograms\/g gel [online]. Available: http:\/\/www.wales.nhs.uk\/sites3\/Documents\/371\/Enc%204%20Appx%202%20ingenol%20mebutate%20%28Picato%29%20ASAR%20W.pdf [Accessed 20 June 2013]."},{"key":"2025082701451859000_51.7.81.27","unstructured":"Scottish Medicines Consortium. Ingenol mebutate gel (Picato) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/851_13_ingenol_mebutate_gel_Picato\/ingenol_mebutate_gel_Picato [Accessed 19 June 2013]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2013.7.0193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:45:31Z","timestamp":1756284331000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2013.7.0193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,10]]},"published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1136\/dtb.2013.7.0193"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2013.7.0193","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}